Market Size in 2021 | Market Forecast in 2026 | CAGR (in %) | Base Year |
---|---|---|---|
USD 44.5 Billion | USD 103.4 Billion | 15.1% | 2021 |
The nicotine replacement therapy market size was worth USD 44.5 billion in 2021 and is estimated to grow to USD 103.4 billion by 2028, with a compound annual growth rate (CAGR) of approximately 15.1% over the forecast period. The report analyzes the nicotine replacement therapy market's drivers, restraints/challenges, and their effect on the demands during the projection period. In addition, the report explores emerging opportunities in the nicotine replacement therapy market.
The use of nicotine patches, inhalers, gums, sprays, and lozenges by smokers that are free of the harmful substances found in tobacco is known as nicotine replacement therapy. Nicotine replacement therapy involves drugs that supply nicotine at a low dose as opposed to smoking, which contains a large amount of nicotine and consequently leads to lung cancer, asthma, and other chronic issues. By reducing or eliminating tobacco use, nicotine replacement treatment lowers the frequency and potency of cravings. Technological improvements and the rise in nicotine replacement treatment (NRT) use encourage the practice of nicotine replacement therapy. Growing public awareness of smoking's harmful effects is a major market driver. The number of smokers is increasing and has topped 1.1 billion individuals worldwide. People are choosing smoking cessation therapies as a result of government measures, including the "affordable care act," insurance rules, and campaigns to raise knowledge of the harmful effects of smoking on health through counseling. More people have been moving to cutting-edge goods due to ongoing technological developments in the field of nicotine replacement therapy. NRT adoption is anticipated to be sped up by innovations like heat-not-burn products, sweetened chewing gum, and lozenges. However, one of the most significant barriers to the market's expansion is the ban on e-cigarettes.
The COVID-19 outbreak has somewhat impacted sales of NRT products. Health agencies like WHO, CDC, and others have recommended smokers give up smoking as a preventive precaution. The lungs are harmed by cigarette smoke, which increases a person's susceptibility to COVID-19. Higher product uptake can be attributed to the populace's growing understanding of the negative consequences of tobacco smoke. The restriction on online sales and the elimination of the ability for consumers to purchase NRT products was first enforced in France. This was mostly done to stop people from stockpiling goods after hearing that nicotine can help fight the COVID-19 virus. The global market will therefore experience significant expansion over the upcoming year, marking a modest growth rate.
Growing understanding of the adverse effects of smoking is driving the market growth
Growing public knowledge of smoking's detrimental consequences is anticipated to be a key market driver. Over 1.1 billion people smoke around the world. Government programs like the "affordable care act," insurance requirements, and campaigns to increase knowledge of the detrimental effects of smoking on health through counseling are all contributing to the rise in the use of nicotine replacement therapies. Favorable reimbursement policies will also accelerate the global nicotine replacement therapy market's expansion.
Myths about NRT that suppress product adoption restraints the market demand
The number of persons who want to stop smoking is decreased despite the widespread understanding of the negative effects of smoking spread via awareness programs, television advertisements, fliers, and other means. Additionally, product uptake remains low despite the introduction of successful NRT treatments and increased public awareness. According to a study by the World Health Organization (WHO), there are myths concerning these products. These include the products' inability to stop smoking, ineffectiveness, adverse effects, and high cost. As a result, the fallacies currently spreading about the items have reduced their adoption rate, resulting in lower sales.
Technological progress is boosting opportunities in the market
People are switching to more advanced goods due to ongoing technological advancements in the market for nicotine replacement therapy. It is predicted that innovations like heat-not-burn products, flavored chewing gum, and lozenges would help NRT become more widely accepted. Tobacco industry behemoths like British American Tobacco have created safer, smokeless substitutes. These advancements differ from conventional cigarettes in that they are recognized by society and have a range of effectiveness, encourage consumer adoption, and boost global nicotine replacement therapy market growth. In the upcoming years, this will open up new market prospects.
The global nicotine replacement therapy market has been segmented on the basis of product, distribution channels, and region.
Based on product, the worldwide nicotine replacement therapy market is segmented into inhalers, gum, transdermal patches, sublingual tablets, lozenges, e-cigarettes, and heat-not-burn tobacco products. In 2021, e-cigarettes had the most significant market share of 52.1%. The market growth is projected to be further fueled by the growing knowledge that e-cigarettes are safer than traditional cigarettes, particularly among the younger generation. The vendors' wide range of customization options, including temperature control and nicotine doses, is anticipated to help the product demand. Additionally, growing e-cigarette technologies like pod systems and squonk mods have gained popularity and user adoption in recent years.
The worldwide nicotine replacement therapy market is segmented as offline and online based on distribution channels. In 2021, the offline segment's revenue share was 83.9%, which was the highest. The segment growth is supported by the accessibility of NRT items such as transdermal patches, gels, gums, e-cigarettes, and heated tobacco products in retail chains like Walgreens and Walmart Stores, Inc. Additionally, the affiliations between hospitals and these chains help the business expand.
North America dominated the nicotine replacement therapy market in 2021
The prevalence of smoking-related ailments and the rise in pro-smoking government measures, along with rising e-cigarette and heated tobacco acceptance, are anticipated to have a beneficial effect on the development of the North American market. This area dominates with the most prominent retail sales of NRT goods in the U.S. and Canada. The number of smokers in the area who adhere to the smoking ban is rising, which has resulted in a more robust demand for products like gum, inhalers, etc. Additionally, the United States has higher smoking cessation rates than other nations, which has resulted in rising sales of these goods. Approximately 68% of Americans have decided to stop smoking, according to a survey conducted by the Centers for Disease Control and Prevention (CDC). As a result, it is projected that this will increase product sales in the years to come. Additionally, gums are more commonly used in the U.S. than other treatments on the market to quit smoking.
Report Scope:
Report Attributes | Report Details |
---|---|
Report Name | Nicotine Replacement Therapy Market Size Report |
Market Size in 2021 | USD 44.5 Billion |
Market Forecast in 2028 | USD 103.4 Billion |
Growth Rate | CAGR of 15.1% |
Number of Pages | 188 |
Forecast Units | Value (USD Billion), and Volume (Units) |
Key Companies Covered | Cipla Inc., Pfizer Inc., Johnson & Johnson Services, Inc., British American Tobacco p.l.c., Philip Morris Products S.A. (Altria Group), Imperial Brands, Glenmark, and Japan Tobacco Inc. |
Segments Covered | By Product, By Distribution Channel, and By Region |
Base Year | 2021 |
Historical Year | 2015 to 2020 |
Forecast Year | 2021 - 2028 |
Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
By Product
By Distribution Channel
By Region
FrequentlyAsked Questions
The increase in smoking cessation programs by businesses, the government, and non-governmental organizations (NGOs) to raise awareness of the harmful effects of smoking is anticipated to result in significant growth for the global market for nicotine replacement therapy in the upcoming years.
According to the report, the global nicotine replacement therapy market size was worth USD 44.5 billion in 2021 and is estimated to grow to USD 103.4 billion by 2028, with a compound annual growth rate (CAGR) of approximately 15.1% over the forecast period.
The North American region is leading the global nicotine replacement therapy market owing to the rising awareness against smoking as well as product development that serves in multiple ways according to user's preferences.
Some of the main competitors dominating the global nicotine replacement therapy market are Cipla Inc., Pfizer Inc., Johnson & Johnson Services, Inc., British American Tobacco p.l.c., Philip Morris Products S.A. (Altria Group), Imperial Brands, Glenmark, and Japan Tobacco Inc.
RelatedNews
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed